<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920920</url>
  </required_header>
  <id_info>
    <org_study_id>EMBRACE 1</org_study_id>
    <nct_id>NCT00920920</nct_id>
  </id_info>
  <brief_title>An International Study on Magnetic Resonance Imaging (MRI)-Guided Brachytherapy in Locally Advanced Cervical Cancer</brief_title>
  <acronym>EMBRACE</acronym>
  <official_title>A International Study on MRI-guided Brachytherapy in Locally Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mount Vernon Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARTI Institute for Radiation Oncology Arnhem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tata Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaposv√°r University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leeds Cancer Centre at St. James</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Postgraduate Institute of Medical Education and Research, Chandigarh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      The standard treatment of locally advanced cervical cancer is radio-chemotherapy including&#xD;
      external beam radiotherapy (EBRT), brachytherapy (BT) and concomitant chemotherapy with&#xD;
      weekly Cisplatin. While image based conformal EBRT is routinely used, prescription and&#xD;
      reporting of BT is still based on specific dose points defined in 2D. Thus, for several&#xD;
      decades the BT dose has most often been prescribed and reported to the Manchester point A&#xD;
      defined according to different traditions.&#xD;
&#xD;
      Recently, a working group from GEC-ESTRO has published recommendations on contouring of&#xD;
      tumour target and organs at risk (OAR) as well as on dose volume parameters to be reported&#xD;
      for image guided BT in definitive radiotherapy for locally advanced cervical cancer. These&#xD;
      recommendations are mainly derived from retrospective single institution experience with MRI&#xD;
      based intracavitary BT. The major advantage of this technique is the possibility to conform&#xD;
      the dose given by BT with regard to both volume (3D) and time (4D). Thus, by repetitive&#xD;
      imaging performed before each BT implant it is possible adapt the dose given by BT to the&#xD;
      anatomy of each individual patient taking into account not only the position of OAR but also&#xD;
      the tumour regression which often is obtained by preceding EBRT and chemotherapy. Based on&#xD;
      the experience collected so far, the image based BT approach is expected to have a major&#xD;
      impact on the clinical outcome with a concomitant decrease in the rates of both local failure&#xD;
      and morbidity.&#xD;
&#xD;
      Aims:&#xD;
&#xD;
        -  To introduce MRI based 3D-4D BT in locally advanced cervical cancer in a multicenter&#xD;
           setting within the frame of a prospective observational study.&#xD;
&#xD;
        -  To establish a bench-mark for clinical outcome with image based BT in a large patient&#xD;
           population with respect to local control, survival, morbidity and QoL&#xD;
&#xD;
        -  To establish a reference material with regard to image based DVH parameters according to&#xD;
           the guidelines from the GEC ESTRO working group.&#xD;
&#xD;
        -  To correlate image based DVH parameters for CTV and for OAR with outcome&#xD;
&#xD;
        -  To develop prognostic and predictive statistical models for clinical outcome including&#xD;
           volumetric, dosimetric, clinical and biological risk factors&#xD;
&#xD;
        -  To establish radiobiological parameter estimates that will allow a precise risk&#xD;
           estimation in individual patients and aid in the development of new treatment protocols&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective observational multicenter study will be performed in patients with locally&#xD;
      advanced cervical cancer considered to be potentially curable by definitive radio-(chemo)&#xD;
      therapy. The patients will be divided and analyzed in three strata according to risk of&#xD;
      recurrence:&#xD;
&#xD;
        1. Small tumours&#xD;
&#xD;
        2. Large tumours favourable response&#xD;
&#xD;
        3. Large tumours with unfavourable response to the initial radio-(chemo) therapy.&#xD;
&#xD;
      A clinical local failure has to be validated by MRI and topographically correlated to the MRI&#xD;
      based BT targets (HR CTV and IR-CTV) and the dose volume parameters of the treatment plan. It&#xD;
      has to be classified as &quot;inside&quot;, &quot;at the edge&quot;, &quot;outside&quot;.&#xD;
&#xD;
      Major events with regard to morbidity have to be reported using 3D imaging information&#xD;
      integrating e.g. clinical examination, endoscopy and MRI. The location of organ damage (i.e.&#xD;
      fistula) has to be identified in 3D and a correlation to the dose volume parameters for the&#xD;
      affected region should be investigated.&#xD;
&#xD;
      Specific Aims&#xD;
&#xD;
        -  To assess prospectively outcome for disease (local control, survival), for morbidity and&#xD;
           for QoL life applying appropriate clinical, imaging and QoL protocols.&#xD;
&#xD;
        -  To test that there are three groups representing different risks of recurrence: small&#xD;
           tumours; large tumours with favourable response; large tumours with unfavourable&#xD;
           response to initial radio-(chemo)therapy.&#xD;
&#xD;
        -  To correlate local control (survival) and dose volume parameters for GTV and CTV for the&#xD;
           overall cohort and for the 3 different risk groups and to establish hazard ratios and&#xD;
           dose effect curves for the primary tumour.&#xD;
&#xD;
        -  To correlate outcome data and dose volume parameters for the different OAR (rectum,&#xD;
           sigmoid, bladder) and to establish hazard ratios and dose effect curves for OAR.&#xD;
&#xD;
        -  To correlate QoL outcome to morbidity outcome.&#xD;
&#xD;
        -  To quantify the change in DVH parameters obtained by image guided dose optimization of&#xD;
           BT in the individual patient.&#xD;
&#xD;
        -  To compare volumetric data on GTV and CTV at diagnosis and during treatment and relate&#xD;
           them to dose volume parameters within the 3 different risk groups of the overall patient&#xD;
           cohort.&#xD;
&#xD;
        -  To evaluate the indicators for quality assessment throughout the whole study period in&#xD;
           order to define systematic and random variations for the different indicators (e.g.&#xD;
           contouring, applicator reconstruction, dose volume assessment).&#xD;
&#xD;
        -  To validate from clinical outcome data the radiobiological equivalence calculations used&#xD;
           for assessing dose and volume parameters in gynaecological radiotherapy.&#xD;
&#xD;
        -  To test if the GYN GEC ESTRO recommendations for BT in cervical cancer are feasible in a&#xD;
           multi-centre setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>local control/morbidity</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>regional control</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life (QoL)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1416</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3D MRI-guided Brachytherapy</intervention_name>
    <description>MRI-based 3D-4D brachytherapy in locally advanced cervical cancer</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients to be included:&#xD;
&#xD;
        Patients with newly biopsy proven squamous carcinoma, adenocarcinoma or adeno-squamous&#xD;
        carcinoma of the uterine cervix, FIGO stage IB, IIA, IIB, IIIA, IIIB and IVA in whom&#xD;
        definitive radiotherapy with curative intent is planned are qualified for the study.&#xD;
        Patients with para-aortic metastatic nodes (stage IVB) to the level of L2 are also eligible&#xD;
        but patients with further dissemination are not.&#xD;
&#xD;
        Staging should as a minimal include gynaecological examination, MRI of the pelvis,&#xD;
        abdominal CT or MRI and chest radiography. Further investigations are applied if necessary&#xD;
        (e.g. cystoscopy, rectoscopy) or normally done according to institutional practice (e.g.&#xD;
        PET-CT).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cancer of the uterine cervix considered suitable for curative treatment with&#xD;
             definitive radio-(chemo)therapy including MRI guided BT&#xD;
&#xD;
          -  Positive biopsy showing squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell&#xD;
             carcinoma of the uterine cervix.&#xD;
&#xD;
          -  Staging according to FIGO and TNM guidelines&#xD;
&#xD;
          -  MRI of pelvis at diagnosis is performed&#xD;
&#xD;
          -  MRI, CT or PET-CT of the retroperitoneal space and abdomen at diagnosis is performed&#xD;
&#xD;
          -  MRI with the applicator in place at the time of (first) BT will be performed&#xD;
&#xD;
          -  Para-aortic metastatic nodes below L1-L2 are allowed&#xD;
&#xD;
          -  Patient informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other primary malignancies except carcinoma in situ of the cervix and basal cell&#xD;
             carcinoma of the skin&#xD;
&#xD;
          -  Metastatic disease beyond para-aortic region (L1-L2)&#xD;
&#xD;
          -  Previous pelvic or abdominal radiotherapy&#xD;
&#xD;
          -  Previous total or partial hysterectomy&#xD;
&#xD;
          -  Combination of preoperative radiotherapy with surgery&#xD;
&#xD;
          -  Patients receiving BT only&#xD;
&#xD;
          -  Patients receiving EBRT only&#xD;
&#xD;
          -  Patients receiving neoadjuvant chemotherapy&#xD;
&#xD;
          -  Contra indications to MRI&#xD;
&#xD;
          -  Contra indications to BT&#xD;
&#xD;
          -  Active infection or severe medical condition endangering treatment delivery&#xD;
&#xD;
          -  Pregnant, lactating or childbearing potential without adequate contraception&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard P√∂tter, Prof., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiotherapy, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MUV</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.embracestudy.dk</url>
    <description>Official homepage of the EMBRACE study</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Richard P√∂tter</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>3D-4D MRI-based Brachytherapy</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Multicenter Clinical Study</keyword>
  <keyword>Locally advanced cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

